The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback